 | Up a level |
Tocchetti, Carlo Gabriele; Farmakis, Dimitrios; Koop, Yvonne; Andres, Maria Sol; Couch, Liam S; Formisano, Luigi; Ciardiello, Fortunato; Pane, Fabrizio; Au, Lewis; Emmerich, Max; Plummer, Chris; Gulati, Geeta; Ramalingam, Sivatharshini; Cardinale, Daniela; Brezden-Masley, Christine; Iakobishvili, Zaza; Thavendiranathan, Paaladinesh; Santoro, Ciro; Bergler-Klein, Jutta; Keramida, Kalliopi; ... (2024). Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology. (In Press). European journal of heart failure Wiley 10.1002/ejhf.3340
Peters, Solange; Stahel, Rolf A; Dafni, Urania; Aix, Santiago Ponce; Massutí, Bartomeu; Gautschi, Oliver; Coate, Linda; López Martín, Ana; van Heemst, Robbert; Berghmans, Thierry; Meldgaard, Peter; Cobo Dols, Manuel; Noguera, Javier Garde; Curioni-Fontecedro, Alessandra; Rauch, Daniel; Mark, Michael T; Cuffe, Sinead; Biesma, Bonne; van Henten, Arjen Mj; Vidal, Óscar Juan; ... (2017). Randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer failing first line platinum-based doublet chemotherapy stratified by Veristrat good versus Veristrat poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung trial. Journal of thoracic oncology, 12(4), pp. 752-762. Elsevier 10.1016/j.jtho.2016.12.017
